The TIMES study is being conducted by the Diabetes Center Berne (DCB) and aims to gain a better understanding of type 1 diabetes (T1D) throughout the menstrual cycle.
This could ultimately improve the quality of life for women with T1D.
DT-Report 2026: Join now
DT-Report 2026: Join now
The survey for the DT Report 2026 is now available – Take part and help shape the future of diabetes technology with us: Whether you are a person living with diabetes or a healthcare professional.
Shape the Future of Diabetes Technology – Your Voice Matters!
Together with diabetesschweiz, the Swiss Society for Endocrinology and Diabetology (SGED | SSED), and partner organizations in Germany and Austria, the DCB is conducting a representative survey on diabetes technology for the DT Report 2026.
Why your participation matters:
Your experiences and feedback are essential for improving the care and further development of diabetes technology in a targeted way. By taking part, you help make barriers and needs visible and create the foundation for future innovations.
Take part now:
Join us and make an important contribution to advancing diabetes technology and improving the quality of life for people with diabetes.
More recent news
TIMES Study | Take part now!
DT-Report 2026: Join now
The survey for the DT Report 2026 is now available – Take part and help shape the future of diabetes technology with...
Alva Innovation wins the DCB Open Innovation Challenge 2025
Bern, 6 November 2025 - The start-up Alva Innovations has won first place in the DCB Open Innovation Challenge. The...
DCB Research AG
Freiburgstrasse 3
3010 Bern
Switzerland
Diabetes Center Berne @ BEA
Diabetes Center Berne @ BEA
DCB joined the Focus Day at BEA in Bern, an event highlighting the latest in healthcare innovation. It was a great opportunity to showcase how Diabetes Center Berne is advancing projects that turn research into practical solutions for improving diabetes care.
Speakers and participants had a great time at the Focus Day at BEA in Bern last Saturday! The event at the new Festhalle brought together innovators from across healthcare, with a spotlight on how we can improve patient care and drive digital medicine forward.
A highlight for DCB was the presentation of CEO Derek Brandt, who shared the vision of Diabetes Center Berne. He emphasized how we are committed to improving the lives of people with diabetes through our cutting-edge translational projects.
It was inspiring to be part of such a forward-thinking event, where healthcare leaders like Christoph Ammann, Simon Rothen, and others shared their insights on the future of medicine in Bern. A big thank you to everyone who contributed to making this event a success!
Focusday at the BEA
More recent news
TIMES Study | Take part now!
The TIMES study is being conducted by the Diabetes Center Berne (DCB) and aims to gain a better understanding of type 1 diabetes (T1D) throughout the menstrual cycle.
This could ultimately improve the quality of life for women with T1D.
DT-Report 2026: Join now
The survey for the DT Report 2026 is now available – Take part and help shape the future of diabetes technology with...
Alva Innovation wins the DCB Open Innovation Challenge 2025
Bern, 6 November 2025 - The start-up Alva Innovations has won first place in the DCB Open Innovation Challenge. The...
DCB Research AG
Freiburgstrasse 3
3010 Bern
Switzerland
Revolutionizing Diabetes Care: How Your Idea Can Make a Global Impact
Revolutionizing Diabetes Care: How Your Idea Can Make a Global Impact
For the fifth time, the Diabetes Center Berne is launching the Open Innovation Challenge with the aim of specifically promoting innovative projects in the field of diabetes management on Swiss and international level. Participating innovtors benefit from professional expert feedback, and the five best projects receive access to a bootcamp. The finalists will receive prize money of up to USD 100,000 and further support from the DCB.
Transform Diabetes Care: Your Innovation Could Change Lives
More than 537 million people worldwide live with diabetes, facing daily challenges in managing their condition. Technological innovations have played a crucial role in simplifying diabetes management.
The DCB Open Innovation Challenge, launched in 2021, aims to bridge these gaps by fostering translational research in diabetes technology. Our goal is to identify groundbreaking solutions that enhance the quality of life for those affected by diabetes. Whether you’re a researcher, healthcare professional, start-up founder, or someone living with diabetes, your ideas are invaluable. We’re seeking diverse perspectives and innovative solutions to push diabetes technology forward.
Join and benefit
Following the initial selection phase, the Top 15 teams will enter a mentoring program with expert guidance. From there, the Top 5 teams will be chosen to participate in an exclusive Bootcamp in Switzerland (September 8–11, 2025), where they will receive tailored coaching, mentoring, and media training.
Additionally, finalists will have the opportunity to present their ideas at the DTM Meeting in the USA from October 27-30, 2025. This event offers a fantastic chance to gain exposure in the USA, thanks to our ongoing collaboration with the Diabetes Technology Society.
Finally, the competition will culminate at the Day of Innovation & Award Ceremony in Bern, Switzerland (November 5, 2025), where an international expert jury will select the winning project.
The winning project will be selected by an international expert jury and rewarded with USD 100,000 in funding and in-kind support – making the DCB Open Innovation Challenge the world’s largest diabetes technology award with international appeal. You will get access to a global network of experts from the field – all while your idea remains entirely yours.
Don’t miss this opportunity to turn your innovation into reality.
Submit your idea by April 30, 2025, on our innovation platform: innovation.dcberne.com
More recent news
TIMES Study | Take part now!
The TIMES study is being conducted by the Diabetes Center Berne (DCB) and aims to gain a better understanding of type 1 diabetes (T1D) throughout the menstrual cycle.
This could ultimately improve the quality of life for women with T1D.
DT-Report 2026: Join now
The survey for the DT Report 2026 is now available – Take part and help shape the future of diabetes technology with...
Alva Innovation wins the DCB Open Innovation Challenge 2025
Bern, 6 November 2025 - The start-up Alva Innovations has won first place in the DCB Open Innovation Challenge. The...
DCB Research AG
Freiburgstrasse 3
3010 Bern
Switzerland
SNAQ Launches AI-Powered Glucose Prediction feature
SNAQ Launches AI-Powered Glucose Prediction feature
SNAQ has introduced a groundbreaking AI-driven feature that predicts glucose responses before meals, revolutionizing diabetes care.
The new meal glucose prediction tool allows CGM users to anticipate their body’s reaction to food using a proprietary deep learning model and a unique digital twin approach. This innovation offers highly personalized insights for improved glucose control.
SNAQ also secured new funding led by the Diabetes Venture Fund at Serpentine Ventures, reinforcing investor confidence despite a tough market. CEO Aurelian Briner emphasized the company’s commitment to scaling innovations and transforming diabetes care. Looking ahead, SNAQ plans to introduce more AI-driven advancements to empower individuals in managing their health.
For more details, read the full press release or visit SNAQ’s website to learn more about their innovations in diabetes care.
More recent news
TIMES Study | Take part now!
The TIMES study is being conducted by the Diabetes Center Berne (DCB) and aims to gain a better understanding of type 1 diabetes (T1D) throughout the menstrual cycle.
This could ultimately improve the quality of life for women with T1D.
DT-Report 2026: Join now
The survey for the DT Report 2026 is now available – Take part and help shape the future of diabetes technology with...
Alva Innovation wins the DCB Open Innovation Challenge 2025
Bern, 6 November 2025 - The start-up Alva Innovations has won first place in the DCB Open Innovation Challenge. The...
DCB Research AG
Freiburgstrasse 3
3010 Bern
Switzerland
Lisa Koch joins DCB as professor specialising in artificial intelligence and data science
Lisa Koch joins DCB as professor specialising in artificial intelligence and data science
The newly created assistant professorship with tenure track is the third of a total of three professorships in the field of “Diabetes Technology and Artificial Pancreas” jointly created by the University of Bern, the Inselgruppe and the Diabetes Center Berne (DCB).
Background in developing data science products for medical devices
Before taking up her new position, Lisa Koch worked on machine learning for biomedical data analysis. She has a background in academic research as well as developing data science products for medical devices, with a strong focus on technology that can ultimately benefit people’s health in a safe and trustworthy way.
After an undergraduate degree in electrical (BSc) and biomedical engineering (MSc) at ETH Zürich, Switzerland, Lisa Koch did a PhD in machine learning for medical image analysis at Imperial College London, UK. After a post-doc at ETH Zürich, she joined the Swiss wearable medical device startup Ava, where she eventually became the data science team lead. In this position, she came to appreciate the need for demonstrably safe machine learning in healthcare.
Safe, reliable, and effective data science tools
In 2021, Lisa Koch returned to academic research to pursue research on this topic as a group leader for machine learning in medical diagnostics at the Hertie Institute for AI in Brain Health at the University of Tübingen, Germany. In her new role as assistant professor at the University of Bern, her long-term goal is to develop certifiably safe, reliable, and effective data science tools for patient-specific treatment systems in diabetes care.
Derek Brandt, CEO of the DCB adds: “In addition to Lilian Witthauer, professor in the field of sensor technology, and José Garcia Tirado, professor for technology-assisted precision medicine, we have taken a third and important step with Professor Koch for the topic of artificial intelligence (AI) and data science in diabetes care. This enables us to further strengthen our international pioneering role in the field of translational diabetes technology research. We will continue doing everything we can to improve daily life for people with diabetes”.
More recent news
TIMES Study | Take part now!
The TIMES study is being conducted by the Diabetes Center Berne (DCB) and aims to gain a better understanding of type 1 diabetes (T1D) throughout the menstrual cycle.
This could ultimately improve the quality of life for women with T1D.
DT-Report 2026: Join now
The survey for the DT Report 2026 is now available – Take part and help shape the future of diabetes technology with...
Alva Innovation wins the DCB Open Innovation Challenge 2025
Bern, 6 November 2025 - The start-up Alva Innovations has won first place in the DCB Open Innovation Challenge. The...